InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Tiger Money PremiumMember
05/28/24 11:53 AM
profile icon
Suomalainen Free
05/26/24 12:33 PM
profile icon
trader59 PremiumMember
05/26/24 11:20 AM
profile icon
trader59 PremiumMember
05/26/24 11:18 AM
profile icon
trader59 PremiumMember
05/26/24 11:16 AM
profile icon
hssbwwmp Free
05/24/24 1:00 AM
profile icon
chumfm Free
05/22/24 7:21 PM
profile icon
Tiger Money PremiumMember
05/22/24 11:20 AM
profile icon
maryj55555 Free
05/21/24 9:04 AM
profile icon
maryj55555 Free
05/21/24 8:44 AM
profile icon
Tiger Money PremiumMember
05/20/24 5:06 PM
profile icon
Suomalainen Free
05/19/24 8:52 AM
profile icon
hssbwwmp Free
05/18/24 6:52 PM
profile icon
hssbwwmp Free
05/17/24 1:54 PM
profile icon
hssbwwmp Free
05/17/24 12:16 PM
profile icon
White Shadow Free
05/17/24 7:46 AM
profile icon
hssbwwmp Free
05/16/24 5:32 PM
profile icon
chumfm Free
05/14/24 6:49 PM
profile icon
radly Free
05/14/24 5:54 PM
profile icon
chumfm Free
05/14/24 1:35 PM
profile icon
chumfm Free
05/14/24 11:38 AM

Sunshine Biopharma Inc (SBFM) RSS Feed

Followers
760
Posters
Posts (Today)
1
Posts (Total)
113669
Created
10/27/08
Type
Free
Moderators
9/20/23 is the date for their "3rd" consecutive failure to Satisfy NASDAQ Listing Requirements.

SUNSHINE BIOPHARMA, INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

From: https://www.marketscreener.com/quote/stock/SUNSHINE-BIOPHARMA-INC-111313819/news/SUNSHINE-BIOPHARMA-INC-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-or-Stan-43333937/

The Company has a period of 180 calendar days from March 24, 2023, or until September 20, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before September 20, 2023, the bid price of the Company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement.

SEC Charges Former CEO of Biotech Company CytoDyn with Fraud, Insider Trading: https://www.sec.gov/news/press-release/2022-232
Is SBFM next for making similar claims? SBFM uplisted around $9 and dropped to $0.62 cents in a matter of months and received a delisting notification warning from NASDAQ.


SUNSHINE BIOPHARMA INC
ANTI CANCER DRUGS
ANTI CORONA VIRUS RESEARCH








FORM 4 AWARDED TO CEO FOR CONTRIBUTION AND CREATION OF CORONA

VIRUS TREATMENT PATENT. ( 0.10CENT LIQUIDATION VALUE)
 
 
 





 

































"The Future Of Medicine"
 

http://sunshinebiopharma.com

https://mobile.twitter.com/sunshinepharma_

 
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 
 

Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 
 




Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697
 

Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.


Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options
 
 
Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.
Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 
SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals
 

 
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.
 
Intellectual Property
 
We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
 
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464, Camille.sebaaly@sunshinebiopharma.com
 

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

http://corporatestock.com

                                                          
https://www.sunshinebiopharma.org/
 
9/20/23 is the date for their "3rd" consecuti